CellAge: Targeting Senescent Cells with Synthetic Biology | Lifespan.io Crowdfunding CampaignA thirty percent improvement in mice sounds great, but what works for mice often doesn't work with humans!

Not only does aging have a negative effect on the quality of life among the elderly but it also causes a significant financial strain on both private and public sectors. As the proportion of older people is increasing so is health care spending. According to a WHO analysis, the annual number of new cancer cases is projected to rise to 17 million by 2020, and reach 27 million by 2030.

Human Longevity, Inc.This company is focused on extending the healthy, "high performance" human lifespan. The company was co-founded by J. Craig Venter. He is famous for leading the team that sequenced the second human genome. (Some say it was a tie for first place and some say his team finished a few weeks later than the other team.) Venter is also active in the field of synthetic genomics.

Human Longevity, Inc. (HLI), was founded by leaders in genomics with the ultimate goal of giving everyone access to the power of data-driven health intelligence. HLI combines state-of-the-art DNA sequencing and expert analysis with machine learning, to help change medicine to a more data-driven science. With a multidisciplinary team of research scientists, computing experts and physicians, we are empowering every part of the healthcare system to work more efficiently.

The First Rejuvenation Therapy Reaches Human Trials Another step on the journey from theory to practice...

This is the first true rejuvenation therapy to reach clinical trials in humans that follows the repair approach to aging as advocated by Dr. Aubrey de Grey of the SENS Research Foundation. The removal of these problem cells has long been suggested as a way to combat age-related ill health, and, finally, we have reached the point at which over a decade of research is ready to be put to the test.

Want to live for ever? Flush out your zombie cells This relates directly to ApoptoSENS - Targeted ablation. Death-resistant cells.

Developing therapies to kill senescent cells is a burgeoning part of the wider quest to defeat ageing and keep people healthier longer. To date about a dozen drugs have been reported that can mop up zombie cells. Clearance of the cells in mice has been shown to delay or alleviate everything from frailty to cardiovascular dysfunction to osteoporosis to, most recently, neurological disorders – though whether killing senescent cells extends life is complicated.